Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.59 |
| ▸ | HTR1A | P08908 | 3/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.54 |
| ▸ | HTR6 | P50406 | 6/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.46 |
| ▸ | HTR3B | O95264 | 3/20 | 0.46 |
| ▸ | HTR3A | P46098 | 3/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17050468 | 0.88 | MRGPRX4 (0.58) | SLC6A4HTR6LRRK2MRGPRX4NPC1 | |
| SCHEMBL2766477 | 0.84 | HTR1A (0.59) | SLC6A4HTR1ASLC6A2SLC6A3ADRB1 | |
| Hydrochloric Acid SCHEMBL8888785 | 0.83 | HTR1A (0.61) | SLC6A4HTR1ASLC6A2SLC6A3ADRB1 | |
| SCHEMBL19381516 | 0.82 | HTR1A (0.67) | SLC6A4HTR1ASLC6A2SLC6A3HTR6 | |
| SCHEMBL23259461 | 0.81 | HTR1A (0.55) | SLC6A4HTR1ASLC6A2SLC6A3HTR6 | |
| SCHEMBL19381132 | 0.81 | HTR1A (0.66) | SLC6A4HTR1ASLC6A2SLC6A3HTR6 | |
| SCHEMBL1847696 | 0.80 | HTR6 (0.56) | SLC6A4HTR1ASLC6A2SLC6A3HTR6 | |
| SCHEMBL1845491 | 0.79 | HTR6 (0.59) | SLC6A4HTR1ASLC6A2SLC6A3HTR6 | |
| SCHEMBL4930887 | 0.79 | HTR6 (0.62) | SLC6A4HTR1ASLC6A2SLC6A3ADRB1 | |
| SCHEMBL2767154 | 0.78 | ADRB1 (0.56) | SLC6A4HTR1AADRB1HTR6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-1627871-B1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2010-04-14 | — | — | EP | disclosed |
| CN-100467449-C | Cyclic aminophenyl sulfamate derivative | ASKA PHARM CO LTD (JP) | 2009-03-11 | — | — | CN | disclosed |
| US-7449466-B2 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1750727-A2 | KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| CN-1823039-A | Cyclic aminophenyl sulfamate derivative | ASKA PHARM CO LTD (JP) | 2006-08-23 | — | — | CN | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
| WO-2005117909-A2 | KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | SLC6A4 1148/4885HTR1A 2511/4885SLC6A2 1829/4885 |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | SLC6A4 3920/4885HTR1A 2254/4885SLC6A2 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.